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EDITORIAL Open Access
Uniting to end the TB epidemic: advances
in disease control from prevention to
better diagnosis and treatment
Ibrahim Abubakar1,2*, Marc Lipman2,3, Timothy D. McHugh2,4 and Helen Fletcher5,6
Abstract
Tuberculosis is a major global cause of morbidity and mortality. Despite recent advances in containing the
epidemic, several challenges continue to slow progress towards elimination including the continuing impact of
drug resistant disease, and the lack of appropriate tools. Curtailing the transmission of tuberculosis remains a
challenge especially in high burden countries. New developments in measuring correlates of protection are
urgently needed to support the evaluation of vaccines. Similarly, despite progress in molecular diagnostics, better
tools are required to identify resistance to antibiotics in multi and extensively drug resistant tuberculosis. Whole
Genome Sequencing may lead to the next generation of assays to rapidly detect resistance and evaluate transmission.
Advances on shortening treatment are hampered by the lack of a biomarker of cure which obviates the current long
wait for relapses in trials. New research is urgently needed to support development of new vaccines and better
diagnostics tools and shorter treatment for drug sensitive and resistant tuberculosis.
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Editorial
Tuberculosis (TB) is a leading global cause of morbidity
and mortality due to an infectious agent [1]. The World
Health Organization (WHO) estimates that levels of
TB have been declining [1]. Unfortunately, multi drug
resistant tuberculosis (MDR-TB) has emerged as a major
problem globally with nearly half a million cases of
MDR-TB diagnosed annually [1].
The WHO developed The End TB Strategy [2] as a
response to the global TB epidemic. In keeping with
the sustainable development goal (SDG) ambition to
rid the world of major infectious disease killers including
TB, HIV and malaria, the End TB Strategy has a vision of
a world free of tuberculosis – zero deaths, disease and
suffering due to TB by 2035. The strategy has 3 pillars;
integrated patient centered care, bold policies and support
systems and intensified research and innovation.
To mark this year’s World TB Day which has the fitting
theme “Unite to end TB” the journals BMC Medicine and
BMC Infectious Diseases, in collaboration with the TB
centres at the London School of Hygiene and Tropical
Medicine and University College London, have developed
a collection of articles summarizing key advances and gaps
in knowledge on TB. Published primary studies and
reviews in this series include transmission studies, the
diagnosis of TB and associated drug resistance, treat-
ment and reports investigating immune correlates and
the development of vaccines.
Transmission
Transmission of Mycobacterium tuberculosis (Mtb) espe-
cially in high burden settings is a major problem [3].
While our understanding of several aspects of TB trans-
mission has improved over the last two decades due to
innovative technology such as molecular fingerprinting,
geographical information systems, improved tests for TB
infection, cough studies, mathematical modelling and
other analytical tools, much remains poorly elucidated.
The occurrence of TB is driven by HIV co-infection,
increasing levels of co-morbidities such as diabetes,
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suboptimal housing and living standards and social
deprivation. However the extent to which each of these
factors determine the global trend is less clear. In low inci-
dence, high income countries, the key drivers of TB in-
clude homelessness, drug misuse, history of imprisonment
and disease occurring in migrants from high TB incidence
countries [4, 5].
Developments such as whole genome sequencing (WGS)
with its potentially greater resolution in distinguishing
linked cases, are beginning to provide a greater insight
into important questions such as the genetic related-
ness of strains allowing the more efficient investigation
of outbreaks. Witney and colleagues provide examples
of local and published incidents and outbreaks where
WGS has been used to improve the discriminatory ability
of existing technology and to provide further information
on missed transmission events [6]. By contrast, Hatherell
and colleagues systematically reviewed studies using WGS
to investigate transmission, outlining several areas of
uncertainty. The limitations outlined were affected by the
level of diversity, the depth of sequencing, available epi-
demiological data, prevalence of TB and therefore conse-
quent level of new infection versus re-infection as well as
mixed infection versus the rate of microevolution [7]. Both
reviews identified the need for further research including
the development of better bioinformatics tools.
In a study examining contact patterns between adults,
youths and children in different settings in Zambia and
South Africa, McCreesh and colleagues, found marked
variation in the type of building where contact happens
and the extent of mixing of age groups [8]. While these
data are limited to specific sites in two high burden set-
tings, they suggest the need to consider evaluating such
information prior to any intervention.
Biomarkers and immune correlates for
tuberculosis vaccine development
There is an urgent need for an effective vaccine to protect
against adult, pulmonary TB disease if we are to reduce
transmission of TB and accelerate the current decline in
global TB incidence. Immune correlates could help to ac-
celerate TB vaccine development through 1) identification
of promising TB vaccine candidates in pre-clinical or early
clinical development 2) for targeted recruitment of indi-
viduals at risk of development of TB disease into efficacy
trials 3) accurate identification of trial participants who
are infected with TB 4) for early identification of partici-
pants who develop TB disease 5) as a substitute for clinical
efficacy and 6) to ultimately further our understanding of
the vaccine inducible immune mechanisms important for
protection from TB disease.
Progress is being made in the development of tools for
screening pre-clinical vaccine candidates based on func-
tional ability to restrict the growth of mycobacteria rather
than any single immune component. Examples of this in-
clude the mycobacterial growth inhibition assay (MGIA)
which can also be used in early phase human clinical trials
for identification of promising vaccine candidates. The
ability to detect a vaccine effect against TB infection or TB
disease is limited by our ability to accurately diagnose
these states. Haas and colleagues describe how tran-
scriptomics, proteomics and metabolomics are aiding
the accurate and rapid diagnosis of TB infection and
active TB disease [9]. In addition to aiding clinical deci-
sions such markers can be used in TB vaccine trials to
increase the accuracy of a TB infection or disease end
point. Infants vaccinated with BCG have highly diverse
immune responses, which reflect underlying differences
in monocyte quantity and phenotype. These differences
may impact on TB vaccine efficacy and should be taken
into account during efficacy testing of candidate TB
vaccines.
Diagnosis, drug resistance and treatment
In many settings, smear microscopy, chest x-ray and
bacterial culture remain the mainstay of TB diagnosis.
While recent advances in molecular diagnostics are
changing the landscape for the diagnosis of TB, the accur-
acy of such tests in many subpopulations such as children
is still poor. The response to emergence of drug resistance
in an individual, or indeed at a programmatic level, re-
quires robust information about the drug resistance profile
of the Mtb strain involved. Obtaining this information by
conventional microbiology is too slow to be of use, but the
advent of molecular tools has facilitated a rapid, though
imperfect picture of resistance. The importance of an indi-
cation of drug sensitivity is highlighted by the paper by
Martin and colleagues, which demonstrates that the se-
lective use of molecular tools can lead to a significant
under identification of drug resistance and the concomi-
tant failure to treat adequately [10]. The authors call for
investment in services to allow the microbiological diag-
nosis to be completed. Of course tools such as the Xpert
MTB/RIF, have a lot to offer in this respect; but this pro-
vides evidence of rifampicin resistance and presumptive
evidence of multi-drug resistance.
The increased accessibility of WGS has begun to
change the diagnostic landscape, at least in high income
settings. Thus, Witney and colleagues describe how WGS
methods are being adapted for diagnostic use, including
rapid identification of single nucleotide polymorphisms
(SNPs) associated with known drug resistance [6]. This
approach is already in use to inform the management of
patients with complex drug resistance patterns in the ab-
sence of timely phenotypic tests. However, the authors
rightly point to the areas that require development not
least the need for a robust and user friendly bioinformatics
pipeline. A key piece of information that is required to
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underpin this is the ability to correlate drug resistance
with a SNP. It is not always possible to identify the ne-
cessary phenotype for sequence analysis and so Phelan
and colleagues present a modelling approach to map
potential resistance genotypes [11]. Using protein
structure prediction they are able to predict polymor-
phisms associated with resistance. They propose that
this approach can be used to inform the development
of novel diagnostics with improved predictive value
for phenotypic drug resistance.
Thus, we see that appropriate diagnosis of drug resist-
ance, like TB diagnosis generally, is an area in develop-
ment. The power of molecular tools needs to be applied
carefully, but the emerging use of WGS and the associ-
ated analysis offers a real opportunity to provide rapid
and robust drug sensitivity data in a timely fashion.
Treatment for drug sensitive TB remains stubbornly
at six months despite efforts to improve upon this.
Microbiological indicators of treatment response that
can discriminate between different regimens and also
predict long term clinical outcome at an individual patient
level would be of great value. The REMoxTB trial, which
compared two 4 month regimens containing moxifloxacin
to standard 6 month treatment and where cultures were
obtained weekly for 8 weeks and monthly thereafter,
provides an opportunity to assess the performance of a
variety of different measures of sputum culture conver-
sion. Phillips and colleagues show that whilst there is
an advantage in using continuous endpoints (which
capture time on treatment) better than measuring the
proportion of negative cultures at a given time, none
were discriminatory enough to be used as either a trial
surrogate endpoint or as an indicator of individual patient
outcome [12].
Phillips and colleagues showed that patient factors
were often most important in predicting outcome. The
study by Ranzani and colleagues, based in Sao Paulo
State, Brazil, highlights this. Here, successful treatment
outcome was directly related to an individual’s social
circumstances – with less than half of the homeless
population studied having a favourable outcome (43 %
compared to 83 % in the comparator group) [13]. This
was mainly due to large numbers being lost to follow
up or dying. Although the number of homeless subjects
was relatively small at 3 %, they were a population with
high rates of HIV co-infection, and hence had consider-
able health needs beyond TB. As is frequently the case,
this study emphasises the importance of an engaged
and co-ordinated societal response if we are to control
TB. In this collection of articles, Phillips and colleagues
describe an innovative approach, the “STEP trial design”,
which may accelerate regimen development by ensuring a
move towards simpler and shorter later phase evaluation
of drug regimen [14].
Conclusion
Ending the global TB epidemic by 2035 will require re-
search to develop the tools to accelerate progress beyond
that possible with current diagnostics, treatment regi-
men, vaccines and public health measures. The studies
published in this series demonstrate some of the pro-
gress that has been made to date. However, they also il-
lustrate the gaps requiring continued and reinvigorated
funding if we are to achieve the SDG goal of ridding the
world of TB.
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